

## Herantis Pharma to Participate in Three Upcoming Virtual Investor Conferences

Herantis Pharma Plc  
Company Release 4 March 2021 at 8:00 a.m. EET  
Press Release

**Herantis Pharma Plc (“Herantis”)**, an innovative clinical stage biotech company pioneering new disease modifying and regenerative biologic and gene therapies, today announced that Craig Cook, Chief Executive Officer, will be participating at the upcoming virtual investor conferences, where he will be presenting and holding 1x1 meetings.

**Event:** H.C. Wainwright Global Life Sciences Conference

**Format:** Presentation & 1x1’s

**Dates:** March 9 – 10, 2021

**Webcasting link:** <https://journey.ct.events/view/e89fea7e-ce72-4238-a8b1-94459dd7fb9e>

The session time is on-demand and is for March 9 starting at 7:00 am (EST), archived for 90 days.

**Event:** Carnegie Nordic Healthcare Virtual Seminar 2021

**Format:** Presentation & 1x1’s

**Dates:** March 9 – 12, 2021

**Presentation:** March 12<sup>th</sup>, 2021 at 09:00 a.m. CET/ 10:00 a.m. EET

**Event:** BIO-Europe Spring Digital 2021

**Format:** Presentation & 1x1’s

**Dates:** March 22 – 25, 2021

**Presentation:** On-demand after March 22, 2021 when registered for BIO-Europe Spring Digital 2021

**For more information, please contact:**

Julie Silber/Gabriela Urquilla

Tel: +46 (0)7 93 486 277/+46 (0)72-396 72 19

Email: [ir@herantis.com](mailto:ir@herantis.com)

**Certified Advisor: UB Securities Ltd, Finland: +358 9 25 380 225, Sweden: +358 40 5161400**

**Company website: [www.herantis.com](http://www.herantis.com)**

### **About Herantis Pharma Plc**

Herantis Pharma Plc is an innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches. Leveraging deep scientific brilliance in protein dysregulation for neurodegenerative diseases,

and growth stimulation in lymphatic diseases, Herantis is advancing a rich pipeline of regenerative biological and gene therapies for high impact diseases. These include i. CDFN biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson's disease and other neurodegenerative diseases, and ii. Lymfactin® VEGF-C gene therapy for restoring lymphatic structure and function for the treatment of oncology related secondary Lymphedema and other lymphatic based diseases. Herantis is pursuing disease modifying treatments that slow, stop, or even reverse the course of diseases, and bring much needed innovation to these underserved diseases. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.

For more information, please visit <https://www.herantis.com>